MedTrace Logo

Depakote ER in Bipolar Depression

NCT00186186 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-04-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.

Conditions

  • Depression, Bipolar

Interventions

DRUG

Depakote ER

Depakote ER

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Terence A. Ketter, MD · Stanford University, Department of Psychiatry and Behavioral Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186186 on ClinicalTrials.gov